Short answer
Corcept Therapeutics Inc (CORT) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Corcept Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Corporate update accompanying quarterly results
- Full financial figures and management commentary in Exhibit 99.1 press release
Item 7.01 · Regulation FD Disclosure
- Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
- Exhibit 99.1 contains the substantive earnings figures and business developments for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $340.5M, up 64% year over year, led by Lifyorli revenue $91.4M and Korlym revenue $249.1M
- Net income $126.8M, up from $19.7M, with diluted EPS $1.01 versus $0.16
- Cash and investments $662.3M, including $43.7M of Q3 share repurchases, strengthening funding for pipeline expansion
- 2026 revenue guidance reiterated at $1.1-$1.2B, supporting continued commercial momentum expectations
- Key catalysts: relacorilant PDUFA date December 17, 2026, potential European approval by year-end, and BELLA Part A results showing 7.2-month median PFS and 59% ORR
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Corcept Therapeutics Inc 8-K filings
Get the next CORT 8-K as it lands
Follow CORT for push alerts, or ask the research agent what this filing means.